RBC Capital Reaffirms Their Buy Rating on Tenet Healthcare (THC)
I'm PortAI, I can summarize articles.
RBC Capital's Ben Hendrix reaffirmed a Buy rating on Tenet Healthcare (THC) with a $252 price target. Hendrix, who covers the Healthcare sector, has an average return of 4.6% and a 51.76% success rate. Morgan Stanley also maintained a Buy rating with a $247 price target. This reflects continued confidence in Tenet Healthcare's stock potential.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments